Reduced Dosage Strategies May Expand Access to Expensive Cancer Therapies

Overview

A phase 3 trial in India demonstrated that an ultra-low dose of nivolumab combined with chemotherapy significantly improved overall survival in patients with advanced head and neck squamous cell carcinoma. This approach offers a more affordable alternative to standard treatments, potentially increasing access in low-income nations.

Background

Access to effective cancer therapies remains a significant challenge in low-income countries, where high costs limit treatment options. Head and neck squamous cell carcinoma is prevalent in regions like India, yet less than 3% of eligible patients receive immunotherapy. Exploring reduced dosage strategies could enhance treatment accessibility and outcomes for these patients.

Data Highlights

Key Findings

• Patients receiving TMC-I had a median overall survival of 10.3 months compared to 6.2 months for standard chemotherapy.
• 46% of patients on TMC-I were alive after one year, versus 23% in the control group.
• TMC-I was associated with approximately 10 percentage points lower rates of grade 3 or higher adverse events compared to standard chemotherapy.
• The study suggests that ultra-low dose nivolumab can provide a cost-effective treatment option in resource-limited settings.
• There is growing momentum for trials comparing standard and low-dose immunotherapy approaches, which could inform dosing strategies in high-resource settings.

Clinical Implications

The findings support the consideration of reduced dosage strategies for immunotherapy in low-income countries, potentially improving patient access and outcomes. Clinicians should evaluate the feasibility of implementing similar approaches in their practice to enhance treatment accessibility.

Conclusion

The trial results indicate that lower dosing of immunotherapy can significantly benefit patients in resource-limited settings, highlighting the need for further research into optimal dosing strategies globally.

Related Resources & Content

1. The ASCO Post, 2019 -- How to Save Billions on Cancer Care Costs: The Potential of Value-Based Prescribing in Oncology
2. The ASCO, 2014 -- IOM Workshop Explores Growing Problems in Patient Access to Cancer Drugs
3. The ASCO Post, 2023 -- Distributing Scarce Cancer Drugs Legally and Ethically
4. The ASCO Post, 2023 -- Hypofractionated Radiotherapy May Reduce Burden of Head and Neck Cancer in Low- and Middle-Income Countries
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2026
6. Journal of Clinical Oncology, 2025 -- Efficacy and safety of standard versus extended interval dosing of PD-1/PD-L1 immune checkpoint inhibitors in solid tumors: A meta-analysis of 4,063 patients.
7. PAHO/WHO, 2025 -- WHO updates list of essential medicines to include key cancer, diabetes treatments
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
9. Efficacy and safety of standard versus extended interval dosing of PD-1/PD-L1 immune checkpoint inhibitors in solid tumors: A meta-analysis of 4,063 patients. | Journal of Clinical Oncology
10. WHO updates list of essential medicines to include key cancer, diabetes treatments - PAHO/WHO | Pan American Health Organization